Protein Engineering Market - By Product (Instrument, Reagent, Software & Services), Technology (Irrational, Rational), Protein (Insulin, Monoclonal Antibody, Vaccine, Growth Factor, Coagulation Factor, Interferon), End-use – Global Forecast, 2024 – 2032

Protein Engineering Market Size

Protein Engineering Market size was valued at over USD 2.5 billion in 2023 and is estimated to grow at 15.9% CAGR from 2024 to 2032 due to the growing collaborations and partnerships for fostering innovations and advancements in the field.
 

Researchers and biotech firms are pooling resources and expertise to develop novel techniques for protein modification and designs. This ongoing synergy among industry stakeholders is promising to transform drug discovery and biotechnology leading to the creation of new therapeutics and diagnostics with improved efficacy and specificity for benefiting patients worldwide. For instance, in March 2024, BRAIN Biotech and AMSilk collaborated on protein engineering for enhancing structural proteins for performance materials. This partnership marked the first patent application, showcasing BRAIN Biotech's reliance on protein engineering and bioinformatics for rational protein design.
 

The rising frequency of protein-deficient disorders, such as marasmus and kwashiorkor especially in developing and underdeveloped countries, is also increasing the demand for protein engineering. Scientists are continually developing novel protein-based therapies to combat these conditions while focusing to provide effective treatment options for the affected population.
 

Furthermore, protein engineering will play an increasingly pivotal role in addressing protein-deficient disorders by creating enhanced therapeutic proteins with improved efficacy and accessibility. The ongoing research for focusing on developing cost-effective solutions to ensure that these vital treatments reach those in need across the globe will also favor the industry development. For instance, in May 2023, UNICEF highlighted that nearly half of the deaths in children under 5 years of age stem from undernutrition. This is underscoring the critical role of protein engineering in developing nutritional interventions to combat undernutrition for potentially reducing mortality rates and enhancing child health globally.
 

However, the high development costs and limited clinical validation may hinder the market progress to some extent. Researchers are seeking innovative funding models and conducting ongoing trials to address these challenges. In addition, collaborations between academia, industry, and regulatory bodies will play a vital role in reducing costs and enhancing validation processes, ultimately facilitating the translation of protein engineering research into clinical applications.
 

Protein Engineering Market Trends

The increasing number of government initiatives is driving technological advancements. Governments are actively funding R&D projects for tackling protein-deficient disorders. Scientists are collaborating with policymakers to create innovative protein-based therapies and preventive measures. Moreover, government support will continue to propel the market growth for fostering the creation of more effective and accessible treatments for malnutrition-related diseases. This concerted effort will underscore the commitment to improving global health outcomes and addressing the root causes of protein deficiency.

For instance, the Japanese government's AI research initiative is boosting advancements in biopharmaceuticals, such as RevolKa, a biotech start-up that leverages machine learning to expedite protein engineering.
 

Protein Engineering Market Analysis

Based on product, the reagents segment may exhibit 16.2% CAGR through 2032. Reagents play a crucial role in protein engineering, with researchers continuously refining and developing new ones. These substances enable the manipulation and modification of proteins for various applications from drug development to biotechnology. Subsequently, advancements in reagent technology will further enhance the precision and efficiency of protein engineering processes, further opening new possibilities for therapeutic interventions and scientific discoveries in fields, such as personalized medicine and biomaterials engineering.
 

In terms of technology, the protein engineering market size from the rational protein design segment is expected to reach over USD 6.15 billion by 2032. This expansion is due to the growing prominence of rational protein design as a cornerstone of protein engineering, with scientists applying computational methods to predict and optimize protein structures and functions. This approach is allowing the creation of novel proteins with desired properties for specific applications, such as drug development and biocatalysis.
 

Moreover, ongoing advancements in computational algorithms and molecular modeling techniques will continue to refine rational protein design for enabling the generation of tailor-made proteins with enhanced performance and functionality, thus driving innovation in diverse fields ranging from medicine to materials science.
 

On the basis of protein type, the protein engineering market from the monoclonal antibodies segment is poised for significant growth at 16% CAGR through 2032. Scientists are engineering monoclonal antibodies for targeted therapies, diagnostics, and vaccine development for expanding their applications in treating various diseases, such as cancer and autoimmune disorders. Additionally, continuous refinement of monoclonal antibody design and production techniques will enhance their specificity, potency, and safety profiles. This ongoing innovation will pave the way for more effective and personalized treatments while heralding a new era in precision medicine where monoclonal antibodies play a pivotal role in improving patient outcomes.
 

Based on end-use, the market value from the pharmaceutical & biotechnology segment is predicted to record over USD 4.19 billion by 2032. This is due to the rising protein engineering advancements in pharmaceuticals and biotechnology for continuously improving drug development and biotech applications. Scientists are manipulating protein structures for  enhancing their functions and designing novel molecules for therapeutic purposes. Researchers are also employing cutting-edge technologies to engineer proteins with unprecedented precision for opening new avenues for tackling diseases and improving human health.
 

North America protein engineering market is predicted to record more than USD 3.75 billion by 2032 due to the notable shift towards sustainable and green technologies in the region. Companies are investing in R&D to develop eco-friendly processes for protein engineering. Additionally, there is a rising focus on personalized medicine as healthcare providers are increasingly tailoring treatments to individual patients based on genetic makeup and other factors. Multiple regional firms are also increasingly integrating sustainable practices into protein engineering processes and advancing personalized medicine approaches to provide more targeted and effective treatments for patients.
 

Protein Engineering Market Share

These industry players are developing innovative technologies as well as products and are continuously investing in R&D and expanding their portfolios to meet the evolving market demands. They are also indulging in partnership ventures to widen their global presence and customer base.
 

Protein Engineering Market Companies

Some of the major protein engineering industry players are:

• Agilent Technologies, Inc.
• Amgen Inc.
• Bio-Rad Laboratories, Inc.
• Bristol Myers Squibb Company
• Bruker Corporation
• Danaher Corporation
• Genentech, Inc.
• Integrated DNA Technologies, Inc.
• Lonza Group
• Merck KGaA
• Thermo Fisher Scientific Inc.
• Vertex Pharmaceuticals Incorporated
   

Protein Engineering Industry News

• In April 2023, Adaptyv Biosystems inaugurated a protein engineering foundry for introducing innovative tools for swift and cost-effective validation of AI-designed proteins.
   
• In July 2022, Amgen partnered with Generate Biomedicines to discover and advance protein therapies for five clinical targets across diverse therapeutic areas. The collaboration included a USD 50 million upfront payment for positioning Amgen competitively.
   

Protein engineering market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Instruments
• Reagents
• Software & services

Market, By Technology

• Irrational protein design
• Rational protein design

Market, By Protein Type

• Insulin
• Monoclonal antibodies
• Vaccines
• Growth factors
• Coagulation factors
• Interferon
• Other protein types

Market, By End-use

• Academic research institutes
• Contract research organizations (CROs)
• Pharmaceutical & biotechnology companies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa